Portfolio Holdings Detail for ISIN IE00BKVL7331
Stock Name / Fund iShares Edge MSCI USA Minimum Volatility ESG UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares VI Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300VML6THE3JJOS76
ETF Ticker MVEA.AS(USD) CXE
ETF Ticker MVEA.DE(EUR) CXE
ETF Ticker MVEA.LS(GBP) CXE
ETF Ticker MVEA(USD) Euronext Amsterdam

Holdings detail for REGN

Stock Name	Regeneron Pharmaceuticals Inc
Ticker	REGN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US75886F1075
LEI	549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria: (RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages: Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL: Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors: Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says: Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth: The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN: In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC: Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.: Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00: Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.: D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares Edge MSCI USA Minimum Volatility ESG UCITS ETF USD (Acc) REGN holdings

Date	Number of REGN Shares Held	Base Market Value of REGN Shares	Local Market Value of REGN Shares	Change in REGN Shares Held	Change in REGN Base Value	Current Price per REGN Share Held	Previous Price per REGN Share Held
2025-11-10 (Monday)	1,205	USD 788,962	USD 788,962	0	USD -3,362	USD 654.74	USD 657.53
2025-11-07 (Friday)	1,205	USD 792,324	USD 792,324	0	USD 12,846	USD 657.53	USD 646.87
2025-11-06 (Thursday)	1,205	USD 779,478	USD 779,478	-72	USD -43,153	USD 646.87	USD 644.19
2025-11-05 (Wednesday)	1,277	USD 822,631	USD 822,631	0	USD 20,675	USD 644.19	USD 628
2025-11-04 (Tuesday)	1,277	USD 801,956	USD 801,956	0	USD -18,197	USD 628	USD 642.25
2025-11-03 (Monday)	1,277	USD 820,153	USD 820,153	-37	USD -36,312	USD 642.25	USD 651.8
2025-10-31 (Friday)	1,314	USD 856,465	USD 856,465	0	USD -2,944	USD 651.8	USD 654.04
2025-10-30 (Thursday)	1,314	USD 859,409	USD 859,409	0	USD 1,485	USD 654.04	USD 652.91
2025-10-29 (Wednesday)	1,314	USD 857,924	USD 857,924	-324	USD -214,114	USD 652.91	USD 654.48
2025-10-28 (Tuesday)	1,638	USD 1,072,038	USD 1,072,038	0	USD 113,300	USD 654.48	USD 585.31
2025-10-27 (Monday)	1,638	USD 958,738	USD 958,738	0	USD 12,056	USD 585.31	USD 577.95
2025-10-24 (Friday)	1,638	USD 946,682	USD 946,682	0	USD 3,702	USD 577.95	USD 575.69

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00BKVL7331

Show aggregate share trades of REGN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-06 SELL -72 657.000 641.260 642.834 USD -46,284 650.45 Profit of 548 on sale
2025-11-03 SELL -37 657.460 627.500 630.496 USD -23,328 650.62 Profit of 745 on sale
2025-10-29 SELL -324 652.910 659.980 659.273 USD -213,604 650.59 Loss of -2,814 on sale
2025-10-21 BUY 72 579.340 582.410 582.103 USD 41,911 652.27
2025-10-03 BUY 36 600.000 618.010 616.209 USD 22,184 654.49
2025-10-02 SELL -36 600.000 605.410 604.869 USD -21,775 654.76 Profit of 1,796 on sale
2025-09-24 SELL -108 576.980 577.980 577.880 USD -62,411 657.42 Profit of 8,590 on sale
2025-08-29 SELL -72 580.700 581.250 581.195 USD -41,846 659.38 Profit of 5,629 on sale
2025-08-15 SELL -36 580.410 581.950 581.796 USD -20,945 659.80 Profit of 2,808 on sale
2025-07-09 SELL -36 552.580 558.380 557.800 USD -20,081 673.51 Profit of 4,166 on sale
2025-07-07 SELL -8 538.110 547.590 546.642 USD -4,373 675.13 Profit of 1,028 on sale
2025-06-25 SELL -70 520.290 525.630 525.096 USD -36,757 681.55 Profit of 10,952 on sale
2025-06-17 SELL -70 508.860 523.010 521.595 USD -36,512 688.33 Profit of 11,671 on sale
2025-06-16 SELL -210 522.680 538.200 536.648 USD -112,696 689.45 Profit of 32,087 on sale
2025-05-20 SELL -140 614.790 615.450 615.384 USD -86,154 710.88 Profit of 13,369 on sale
2025-05-14 SELL -35 571.360 580.560 579.640 USD -20,287 714.85 Profit of 4,732 on sale
2025-05-13 SELL -35 574.160 575.050 574.961 USD -20,124 715.98 Profit of 4,936 on sale
2025-05-06 SELL -70 558.520 606.870 602.035 USD -42,142 722.79 Profit of 8,453 on sale
2025-05-01 SELL -35 590.000 593.930 593.537 USD -20,774 725.97 Profit of 4,635 on sale
2025-04-28 SELL -35 610.860 614.830 614.433 USD -21,505 729.50 Profit of 4,027 on sale
2025-04-25 SELL -105 602.640 602.790 602.775 USD -63,291 730.64 Profit of 13,425 on sale
2025-04-15 BUY 35 557.910 575.200 573.471 USD 20,071 742.91
2025-04-14 BUY 35 571.060 574.720 574.354 USD 20,102 744.58
2025-04-10 BUY 105 546.390 571.990 569.430 USD 59,790 748.43
2025-04-09 BUY 35 576.720 580.730 580.329 USD 20,312 750.15
2025-04-08 BUY 175 556.810 586.030 583.108 USD 102,044 752.10
2025-04-07 BUY 105 572.780 591.540 589.664 USD 61,915 753.93
2025-03-31 BUY 210 634.230 640.720 640.071 USD 134,415 759.95
2025-03-07 BUY 35 707.510 729.750 727.526 USD 25,463 777.98
2025-03-04 BUY 70 675.490 697.460 695.263 USD 48,668 780.52
2025-02-18 SELL -105 680.000 689.950 688.955 USD -72,340 792.84 Profit of 10,908 on sale
2025-02-14 SELL -35 673.600 684.000 682.960 USD -23,904 796.57 Profit of 3,976 on sale
2025-02-07 BUY 35 710.000 731.420 729.278 USD 25,525 806.38
2025-01-31 SELL -35 672.980 688.000 686.498 USD -24,027 816.68 Profit of 4,556 on sale
2025-01-02 SELL -35 715.190 726.810 725.648 USD -25,398 835.61 Profit of 3,849 on sale
2024-12-06 BUY 35 778.000 778.120 778.108 USD 27,234 839.30
2024-12-03 SELL -35 749.570 770.000 767.957 USD -26,878 845.30 Profit of 2,707 on sale
2024-11-21 BUY 35 744.500 757.560 756.254 USD 26,469 875.73
2024-11-19 SELL -35 744.600 758.600 757.200 USD -26,502 884.81 Profit of 4,466 on sale
2024-11-18 SELL -35 762.000 762.700 762.630 USD -26,692 889.20 Profit of 4,430 on sale
2024-11-07 SELL -70 824.480 832.530 831.725 USD -58,221 899.80 Profit of 4,765 on sale
2024-11-06 SELL -140 816.650 844.510 841.724 USD -117,841 903.42 Profit of 8,637 on sale
2024-11-01 SELL -105 843.600 862.000 860.160 USD -90,317 927.93 Profit of 7,116 on sale
2024-11-01 SELL -105 843.600 862.000 860.160 USD -90,317 927.93 Profit of 7,116 on sale
2024-10-31 SELL -35 838.200 883.150 878.655 USD -30,753 939.90 Profit of 2,143 on sale
2024-10-31 SELL -35 838.200 883.150 878.655 USD -30,753 939.90 Profit of 2,143 on sale
2024-10-23 SELL -245 941.390 959.600 957.779 USD -234,656 965.42 Profit of 1,872 on sale
2024-10-23 SELL -245 941.390 959.600 957.779 USD -234,656 965.42 Profit of 1,872 on sale
2024-10-22 SELL -35 962.340 972.750 971.709 USD -34,010 968.50 Loss of -112 on sale
2024-10-22 SELL -35 962.340 972.750 971.709 USD -34,010 968.50 Loss of -112 on sale
2024-10-21 SELL -70 968.500 991.240 988.966 USD -69,228 0.00 Loss of -69,228 on sale
2024-10-21 SELL -70 968.500 991.240 988.966 USD -69,228 0.00 Loss of -69,228 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-06	SELL	-72	657.000	641.260	642.834	USD -46,284	650.45 Profit of 548 on sale
2025-11-03	SELL	-37	657.460	627.500	630.496	USD -23,328	650.62 Profit of 745 on sale
2025-10-29	SELL	-324	652.910	659.980	659.273	USD -213,604	650.59 Loss of -2,814 on sale
2025-10-21	BUY	72	579.340	582.410	582.103	USD 41,911	652.27
2025-10-03	BUY	36	600.000	618.010	616.209	USD 22,184	654.49
2025-10-02	SELL	-36	600.000	605.410	604.869	USD -21,775	654.76 Profit of 1,796 on sale
2025-09-24	SELL	-108	576.980	577.980	577.880	USD -62,411	657.42 Profit of 8,590 on sale
2025-08-29	SELL	-72	580.700	581.250	581.195	USD -41,846	659.38 Profit of 5,629 on sale
2025-08-15	SELL	-36	580.410	581.950	581.796	USD -20,945	659.80 Profit of 2,808 on sale
2025-07-09	SELL	-36	552.580	558.380	557.800	USD -20,081	673.51 Profit of 4,166 on sale
2025-07-07	SELL	-8	538.110	547.590	546.642	USD -4,373	675.13 Profit of 1,028 on sale
2025-06-25	SELL	-70	520.290	525.630	525.096	USD -36,757	681.55 Profit of 10,952 on sale
2025-06-17	SELL	-70	508.860	523.010	521.595	USD -36,512	688.33 Profit of 11,671 on sale
2025-06-16	SELL	-210	522.680	538.200	536.648	USD -112,696	689.45 Profit of 32,087 on sale
2025-05-20	SELL	-140	614.790	615.450	615.384	USD -86,154	710.88 Profit of 13,369 on sale
2025-05-14	SELL	-35	571.360	580.560	579.640	USD -20,287	714.85 Profit of 4,732 on sale
2025-05-13	SELL	-35	574.160	575.050	574.961	USD -20,124	715.98 Profit of 4,936 on sale
2025-05-06	SELL	-70	558.520	606.870	602.035	USD -42,142	722.79 Profit of 8,453 on sale
2025-05-01	SELL	-35	590.000	593.930	593.537	USD -20,774	725.97 Profit of 4,635 on sale
2025-04-28	SELL	-35	610.860	614.830	614.433	USD -21,505	729.50 Profit of 4,027 on sale
2025-04-25	SELL	-105	602.640	602.790	602.775	USD -63,291	730.64 Profit of 13,425 on sale
2025-04-15	BUY	35	557.910	575.200	573.471	USD 20,071	742.91
2025-04-14	BUY	35	571.060	574.720	574.354	USD 20,102	744.58
2025-04-10	BUY	105	546.390	571.990	569.430	USD 59,790	748.43
2025-04-09	BUY	35	576.720	580.730	580.329	USD 20,312	750.15
2025-04-08	BUY	175	556.810	586.030	583.108	USD 102,044	752.10
2025-04-07	BUY	105	572.780	591.540	589.664	USD 61,915	753.93
2025-03-31	BUY	210	634.230	640.720	640.071	USD 134,415	759.95
2025-03-07	BUY	35	707.510	729.750	727.526	USD 25,463	777.98
2025-03-04	BUY	70	675.490	697.460	695.263	USD 48,668	780.52
2025-02-18	SELL	-105	680.000	689.950	688.955	USD -72,340	792.84 Profit of 10,908 on sale
2025-02-14	SELL	-35	673.600	684.000	682.960	USD -23,904	796.57 Profit of 3,976 on sale
2025-02-07	BUY	35	710.000	731.420	729.278	USD 25,525	806.38
2025-01-31	SELL	-35	672.980	688.000	686.498	USD -24,027	816.68 Profit of 4,556 on sale
2025-01-02	SELL	-35	715.190	726.810	725.648	USD -25,398	835.61 Profit of 3,849 on sale
2024-12-06	BUY	35	778.000	778.120	778.108	USD 27,234	839.30
2024-12-03	SELL	-35	749.570	770.000	767.957	USD -26,878	845.30 Profit of 2,707 on sale
2024-11-21	BUY	35	744.500	757.560	756.254	USD 26,469	875.73
2024-11-19	SELL	-35	744.600	758.600	757.200	USD -26,502	884.81 Profit of 4,466 on sale
2024-11-18	SELL	-35	762.000	762.700	762.630	USD -26,692	889.20 Profit of 4,430 on sale
2024-11-07	SELL	-70	824.480	832.530	831.725	USD -58,221	899.80 Profit of 4,765 on sale
2024-11-06	SELL	-140	816.650	844.510	841.724	USD -117,841	903.42 Profit of 8,637 on sale
2024-11-01	SELL	-105	843.600	862.000	860.160	USD -90,317	927.93 Profit of 7,116 on sale
2024-11-01	SELL	-105	843.600	862.000	860.160	USD -90,317	927.93 Profit of 7,116 on sale
2024-10-31	SELL	-35	838.200	883.150	878.655	USD -30,753	939.90 Profit of 2,143 on sale
2024-10-31	SELL	-35	838.200	883.150	878.655	USD -30,753	939.90 Profit of 2,143 on sale
2024-10-23	SELL	-245	941.390	959.600	957.779	USD -234,656	965.42 Profit of 1,872 on sale
2024-10-23	SELL	-245	941.390	959.600	957.779	USD -234,656	965.42 Profit of 1,872 on sale
2024-10-22	SELL	-35	962.340	972.750	971.709	USD -34,010	968.50 Loss of -112 on sale
2024-10-22	SELL	-35	962.340	972.750	971.709	USD -34,010	968.50 Loss of -112 on sale
2024-10-21	SELL	-70	968.500	991.240	988.966	USD -69,228	0.00 Loss of -69,228 on sale
2024-10-21	SELL	-70	968.500	991.240	988.966	USD -69,228	0.00 Loss of -69,228 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	208,659	1,635	312,812	66.7%
2025-09-18	236,485	3,679	387,519	61.0%
2025-09-17	229,191	716	370,895	61.8%
2025-09-16	173,632	584	271,020	64.1%
2025-09-15	204,491	251	334,496	61.1%
2025-09-12	117,504	33	222,760	52.7%
2025-09-11	125,478	3,137	286,516	43.8%
2025-09-10	195,068	481	339,885	57.4%
2025-09-09	129,168	994	274,520	47.1%
2025-09-08	250,895	396	527,062	47.6%
2025-09-05	170,149	290	289,566	58.8%
2025-09-04	188,227	2,103	360,619	52.2%
2025-09-03	185,679	344	438,111	42.4%
2025-09-02	191,954	138	476,288	40.3%
2025-08-29	133,226	685	236,726	56.3%
2025-08-28	116,560	2,177	256,675	45.4%
2025-08-27	113,719	465	243,836	46.6%
2025-08-26	210,376	450	400,199	52.6%
2025-08-25	149,130	68	363,377	41.0%
2025-08-22	211,822	3,244	701,770	30.2%
2025-08-21	257,492	3,416	446,439	57.7%
2025-08-20	327,738	572	559,133	58.6%
2025-08-19	118,472	2,191	324,311	36.5%
2025-08-18	146,282	388	277,909	52.6%
2025-08-15	209,923	3,375	441,752	47.5%
2025-08-14	157,569	3,623	429,327	36.7%
2025-08-13	111,342	233	362,786	30.7%
2025-08-12	117,647	171	310,775	37.9%
2025-08-11	129,513	2,676	284,757	45.5%
2025-08-08	128,559	1,038	431,841	29.8%
2025-08-07	166,648	1,560	352,877	47.2%
2025-08-06	176,311	624	397,089	44.4%
2025-08-05	154,257	115	353,744	43.6%
2025-08-04	200,758	1,913	409,897	49.0%
2025-08-01	349,775	3,745	728,720	48.0%
2025-07-31	222,350	476	549,344	40.5%
2025-07-30	106,839	1,689	231,761	46.1%
2025-07-29	149,359	276	292,667	51.0%
2025-07-28	103,687	1,380	245,287	42.3%
2025-07-25	103,783	556	259,069	40.1%
2025-07-24	156,974	2,397	291,677	53.8%
2025-07-23	168,734	1,708	355,372	47.5%
2025-07-22	116,324	617	304,880	38.2%
2025-07-21	98,482	900	250,107	39.4%
2025-07-18	183,174	1,051	391,909	46.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Edge MSCI USA Minimum Volatility ESG UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares VI Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300VML6THE3JJOS76
ETF Ticker	MVEA.AS(USD) CXE
ETF Ticker	MVEA.DE(EUR) CXE
ETF Ticker	MVEA.LS(GBP) CXE
ETF Ticker	MVEA(USD) Euronext Amsterdam